PHIO vs. FGEN, IMMX, LTRN, RPTX, PRLD, RNTX, KALA, CNTB, CELU, and XLO
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include FibroGen (FGEN), Immix Biopharma (IMMX), Lantern Pharma (LTRN), Repare Therapeutics (RPTX), Prelude Therapeutics (PRLD), Rein Therapeutics (RNTX), KALA BIO (KALA), Connect Biopharma (CNTB), Celularity (CELU), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical products" industry.
Phio Pharmaceuticals vs.
FibroGen (NASDAQ:FGEN) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment, valuation and community ranking.
FibroGen received 308 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. However, 63.79% of users gave Phio Pharmaceuticals an outperform vote while only 59.90% of users gave FibroGen an outperform vote.
FibroGen has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.
Phio Pharmaceuticals has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.
In the previous week, FibroGen had 8 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 15 mentions for FibroGen and 7 mentions for Phio Pharmaceuticals. FibroGen's average media sentiment score of 0.26 beat Phio Pharmaceuticals' score of 0.13 indicating that FibroGen is being referred to more favorably in the media.
72.7% of FibroGen shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 2.0% of FibroGen shares are held by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Phio Pharmaceuticals has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
FibroGen currently has a consensus target price of $10.00, indicating a potential upside of 1,316.63%. Phio Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 139.52%. Given FibroGen's higher probable upside, analysts clearly believe FibroGen is more favorable than Phio Pharmaceuticals.
Summary
FibroGen beats Phio Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PHIO) was last updated on 2/22/2025 by MarketBeat.com Staff
Free PHIO Stock Alerts